Safety Profile
Known Safety Concerns
- CYP450 inhibition -- may increase blood levels of many medications
- Antiplatelet effect -- interaction with warfarin and NSAIDs
- Estrogenic activity -- caution in hormone-sensitive cancers
- GI distress, nausea and diarrhea at doses above 1 g per day
Contraindications
- CYP450 inhibition -- may increase blood levels of many medications
- Antiplatelet effect -- interaction with warfarin and NSAIDs
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Resveratrol is a polyphenol from grape skin and Japanese knotweed marketed for cardiovascular health, anti-aging, and sirtuins activation. Despite strong preclinical data, human clinical trials have been disappointing. High doses (1-5 g per day) cause significant GI distress. Resveratrol inhibits CYP450 enzymes and has antiplatelet effects — relevant drug interactions include warfarin and statins. Estrogenic activity is relevant in hormone-sensitive conditions.
Biological and Chemical Classification
- Scientific Name
- trans-Resveratrol
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Metabolic
- Evidence consistency: High consistency across studies (100%)
- CYP450 inhibition -- may increase blood levels of many medications
- Antiplatelet effect -- interaction with warfarin and NSAIDs
- Estrogenic activity -- caution in hormone-sensitive cancers
- GI distress, nausea and diarrhea at doses above 1 g per day
The available scientific evidence for Resveratrol indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 24 მარ 2026, 09:34
Evidence Distribution
-
Observational / other LOW evidence YELLOWProtective effect of trans-resveratrol against excitotoxic retinal injury: Focus on renin-angiotensin system and adenosine interaction. ↗Abdul Malick Sahib MI et al.. Protective effect of trans-resveratrol against excitotoxic retinal injury: Focus on renin-angiotensin system and adenosine interaction.. Exp Eye Res. 2026. PMID:41856304.PMID 41856304 ↗Journal Exp Eye ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41856304/
-
Observational / other LOW evidence YELLOWExperimental and Modeling Assessment of Polyphenol Solubility in Alcohol + Ethyl Acetate Mixtures for Extraction Applications. ↗Montenegro I et al.. Experimental and Modeling Assessment of Polyphenol Solubility in Alcohol + Ethyl Acetate Mixtures for Extraction Applications.. ACS Omega. 2026. PMID:41835587.PMID 41835587 ↗Journal ACS OmegaYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41835587/
-
Observational / other LOW evidence YELLOWBiochemical Profiling of Lead-Induced Lipid Metabolic Dysfunction and Its Amelioration by Bioactive Compounds From Rosmarinus officinalis Ethanol Extract. ↗Qaiser MN et al.. Biochemical Profiling of Lead-Induced Lipid Metabolic Dysfunction and Its Amelioration by Bioactive Compounds From Rosmarinus officinalis Ethanol Extract.. Chem Biodivers. 2026. PMID:41822995.PMID 41822995 ↗Journal Chem BiodiversYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41822995/
-
Observational / other LOW evidence YELLOWThe Role of Reactive Species in Modulating Stilbene Biosynthesis in Grapevine Cells. ↗Gu00f3mez-Copovu00ed E et al.. The Role of Reactive Species in Modulating Stilbene Biosynthesis in Grapevine Cells.. Plant Cell Physiol. 2026. PMID:41804801.PMID 41804801 ↗Journal Plant Cell PhysiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41804801/
-
Observational / other LOW evidence YELLOWIntranasal Resveratrol Plus Carboxymethyl-u03b2-Glucan: A Promising Option in Clinical Practice. ↗Ciprandi G et al.. Intranasal Resveratrol Plus Carboxymethyl-u03b2-Glucan: A Promising Option in Clinical Practice.. Biomolecules. 2026. PMID:41750354.PMID 41750354 ↗Journal BiomoleculesYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41750354/
-
Observational / other LOW evidence YELLOWResveratrol improves cognitive function and quality of life in postmenopausal women. ↗Myhal V et al.. Resveratrol improves cognitive function and quality of life in postmenopausal women.. Pol Merkur Lekarski. 2026. PMID:41746883.PMID 41746883 ↗Journal Pol Merkur LekarskiYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41746883/
-
Observational / other LOW evidence YELLOWImpact of bile salts, biopolymer coatings, and food matrix on bilosome-mediated delivery of trans-resveratrol. ↗Can A et al.. Impact of bile salts, biopolymer coatings, and food matrix on bilosome-mediated delivery of trans-resveratrol.. Food Chem X. 2026. PMID:41624578.PMID 41624578 ↗Journal Food Chem XYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41624578/
-
Observational / other LOW evidence YELLOWEffects of Resveratrol on Browning and Insulin Signaling in Primary Murine Adipocytes: Modulation by Sex and Diabetic Status. ↗Xu X et al.. Effects of Resveratrol on Browning and Insulin Signaling in Primary Murine Adipocytes: Modulation by Sex and Diabetic Status.. Nutrients. 2025. PMID:41515137.PMID 41515137 ↗Journal NutrientsYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41515137/
-
Observational / other LOW evidence YELLOWTrans-resveratrol reduces visible signs of skin ageing in healthy adult females over 40: an 8-week randomized placebo-controlled trial. ↗Rao A et al.. Trans-resveratrol reduces visible signs of skin ageing in healthy adult females over 40: an 8-week randomized placebo-controlled trial.. Front Aging. 2025. PMID:41488277.PMID 41488277 ↗Journal Front AgingYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41488277/
-
Observational / other LOW evidence YELLOWDevelopment and Validation of RP-HPLC Method for trans-Resveratrol in HPu03b2CD-Loaded Stealth Liposomes: Stability and Release Studies. ↗Marwa A et al.. Development and Validation of RP-HPLC Method for trans-Resveratrol in HPu03b2CD-Loaded Stealth Liposomes: Stability and Release Studies.. ACS Omega. 2025. PMID:41487204.PMID 41487204 ↗Journal ACS OmegaYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41487204/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Resveratrol. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Moderate classification for Resveratrol
A score of 4.0 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.